Triple receptor engagement
Retatrutide binds GIP, GLP-1 and glucagon receptors, producing a combined signalling profile distinct from selective agonists.
- GLP-1 receptor activation
- GIP receptor activation
- Glucagon receptor activation
≥99% Purity
Retatrutide GLP-3
Triple Agonist Metabolic Studies
$100.00$75.00/vial with BOGO
Quantity1
Buy 1 Get 1 50% off · auto-appliedAdd 2+ items to cart — every second vial is 50% offOffer Ends 9/15
Same day / next business day dispatch
Free Shipping on orders over $200
Secure Checkout
Third-Party Tested
Money-Back Guarantee
PassedSterility & Endotoxins
PassedNet Content & Purity
Researchers also added
About this compound
Retatrutide is an investigational triple agonist peptide that engages the GIP, GLP-1, and glucagon receptors simultaneously. Published phase-2 literature has characterised its effects on energy intake, glycaemic markers, and adipose mass in controlled clinical settings. Research interest centres on how combined incretin and glucagon signalling changes substrate use compared with single- or dual-receptor agonists.
Triple GIP / GLP-1 / glucagon receptor agonist peptide
- Formula
- C221H342N46O68
- Molecular weight
- 5288.5 g/mol
- CAS / ID
- 2381089-83-2
- Form
- Lyophilized powder
0%
Body-weight change
Phase 2, 48 weeks, 12 mg cohort
0
Receptor targets
GIP, GLP-1 and glucagon
0+
Indexed studies
Peer-reviewed literature on triple agonism
0
Amino acids
Synthetic peptide backbone
How It WorksIncretin signalling Energy balance
How Retatrutide GLP-3 works
The pathways Retatrutide GLP-3 acts on — and what each one does. Signalling pathways studied in preclinical models · illustrative.
Substrate utilisation
Glucagon-receptor engagement has been associated in the literature with increased energy expenditure alongside incretin-mediated appetite signalling.
- Reported reductions in energy intake
- Changes in hepatic lipid markers
- Dose-dependent effects across cohorts
Uses & applicationsMetabolic Glycaemic
What Retatrutide GLP-3 is researched for
The main areas Retatrutide GLP-3 is being studied for — and the study-reported figures behind them.
Body-composition research
Studied in models examining adipose mass, lean mass retention, and weight trajectory over 24–48 week windows.
NEJM 2023
Glucose regulation
Evaluated for HbA1c and fasting-glucose response in type-2 diabetes research cohorts.
Lancet 2023
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
- Body-weight change (48 wk)−24.2%
- HbA1c reductionReduced
- Energy intakeReduced
Figures are representative of published research findings and shown for reference.
Third-Party Verified
Independently tested. Verifiably pure.
Every batch of Retatrutide GLP-3 is sent to an accredited independent laboratory before it ships. Here is what we screen for.
- HPLC Purity AnalysisConfirms the peptide is ≥99% pure
- Mass SpectrometryVerifies the exact molecular identity
- Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass
- Endotoxins (LAL)Bacterial endotoxin levels — Pass
- Sterility TestingNo microbial contamination — Pass
- Net Peptide ContentActual peptide mass per vial verified
Compound Information
Full specification
| Compound | Retatrutide (LY3437943) |
|---|---|
| Molecular formula | C221H342N46O68 |
| Molecular weight | 5288.5 g/mol |
| CAS number | 2381089-83-2 |
| Purity (HPLC) | ≥99% |
| Vial size | 10mg |
| Physical form | Lyophilized white powder |
| Storage | -20 °C, protected from light |
| Reconstitution | Bacteriostatic water |
| Intended use | Laboratory research only — not for human consumption |
FAQ
Common questions about Retatrutide GLP-3
Every Retatrutide lot is assayed by HPLC to ≥99% purity, with mass-spectrometry identity confirmation. The certificate of analysis for your lot is available in the COA library.
Store lyophilized vials at -20 °C protected from light. Once reconstituted with bacteriostatic water, keep refrigerated at 2–8 °C and use within the window described in your protocol.
No. This compound is supplied strictly as a reference material for in-vitro and laboratory research. It is not a drug, supplement, or food, and it is not intended for human or animal consumption.
Yes. Independent third-party laboratories run identity and purity panels on each production lot, and the signed report is archived by lot number.
Published Literature
Peer-reviewed literature
Independent published research indexed from PubMed and peer-reviewed journals — not Zorva Lab claims.
For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Back to catalog